HeartBeat.bio AG

HeartBeat.bio AG is a biotech company founded in 2021 using its next-generation drug discovery platform to develop novel medicines for patients with heart failure. Heart failure is a serious disease with high unmet medical need and a significant lack of innovation, affecting more than 30 million people in major pharmaceutical markets.

HBB's Cardioid Drug Discovery Platform is based on a proprietary iPSC-derived single and multi-chamber cardiac organoid model. We take a holistic human-centric drug discovery approach to get rid of animal models, which are often misleading in predicting clinical outcomes. By combining more physiological human models with state-of-the-art hardware and AI-driven software, HBB expects to overcome the current bottlenecks in preclinical drug discovery to develop drugs faster, more cost-effectively and with a higher probability of success. 

We are pursuing our own drug discovery program and collaborating with pharmaceutical and biotechnology companies to develop new preclinical compounds. Initially, the HBB drug discovery program will focus on different types of cardiomyopathies, myocardial fibrosis and remodeling."